Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Bosutinib shows 'low' vascular, cardiac event risk profile

Bosutinib shows 'low' vascular, cardiac event risk profile

Imatinib-related symptom burden linked to adherence in Indian CML patients

Imatinib-related symptom burden linked to adherence in Indian CML patients

Frontline nilotinib supported for newly diagnosed CP-CML

Frontline nilotinib supported for newly diagnosed CP-CML

Pre-TKI cytokine profiling predicts CP-CML outcome

Pre-TKI cytokine profiling predicts CP-CML outcome

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

Intestinal bacteria can be used to reduce cancer risk, reveals UCLA study

Intestinal bacteria can be used to reduce cancer risk, reveals UCLA study

Researchers reach milestone in developing non-hormonal approach to male contraception

Researchers reach milestone in developing non-hormonal approach to male contraception

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

CCCBD offers promising new investigational therapy to treat childhood ALL

CCCBD offers promising new investigational therapy to treat childhood ALL

High out-of-pocket costs linked to lower use of specialty drugs

High out-of-pocket costs linked to lower use of specialty drugs

Promising UCLA discovery could lead to new method for improving cancer treatments

Promising UCLA discovery could lead to new method for improving cancer treatments

Gleevec could be novel therapeutic agent for type 2 diabetes

Gleevec could be novel therapeutic agent for type 2 diabetes

Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

Mutations in cancerous lymphoma cells break through four protein locks

Mutations in cancerous lymphoma cells break through four protein locks

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Four key genes govern growth, multiplication of blood stem cells

Four key genes govern growth, multiplication of blood stem cells

Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

MRX-2843 treatment improves survival of acute myeloid leukemia patients

MRX-2843 treatment improves survival of acute myeloid leukemia patients

CIRM approves $6.3 million grant to support research on novel stem cell-based therapy for ALS

CIRM approves $6.3 million grant to support research on novel stem cell-based therapy for ALS

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.